Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polycystin-2-like protein 2 (PKD2L2) is a member of the transient receptor potential (TRP) channel superfamily, specifically the polycystin (TRPP) subfamily. It is a predicted non-selective cation channel that may function as a calcium-permeable channel in cellular membranes, particularly in primary cilia and possibly involved in mechanical stimulus detection. PKD2L2 has strong homology to the canonical polycystin-2 (PKD2), which is well established in the pathogenesis of autosomal dominant polycystic kidney disease, but PKD2L2 itself is not directly implicated in major human diseases. The protein likely forms tetrameric channels and shares structural features (such as the mucolipin domain) with other TRPP channels. Functionally, it is thought to participate in cellular signaling processes regulated by changes in intracellular calcium, though its physiological role in humans remains incompletely understood. Amiloride can inhibit its channel activity in experimental models, but no therapies targeting PKD2L2 are in clinical use.
Channel inhibition (e.g., amiloride blocks cation flow through the channel in experimental systems)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polycystin-2-like protein 2 (PKD2L2).